-
Article
Open AccessNucleotide excision repair is a potential therapeutic target in multiple myeloma
Despite the development of novel drugs, alkylating agents remain an important component of therapy in multiple myeloma (MM). DNA repair processes contribute towards sensitivity to alkylating agents and therefo...
-
Article
Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy
Monoclonal IgM anti-myelin-associated glycoprotein (MAG) antibody-related peripheral neuropathy (anti-MAG neuropathy) is predominantly a demyelinating sensory neuropathy with ataxia and distal paresthesia. The...
-
Article
Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients
We retrospectively reviewed 49 patients with light chain (LC) Fanconi syndrome (FS). Patients presented with chronic kidney disease (median estimated glomerular filtration rate (eGFR) of 33 ml/min/1.73 m2) and tu...
-
Article
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
-
Article
Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy
We retrospectively studied a series of 23 patients (median age 50 years, range 29–59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous–allogeneic tandem approach. Tandem tr...
-
Article
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
This retrospective analysis investigated the prognostic value of del(13) and t(4;14) abnormalities and the impact of prior treatment on outcomes in 207 heavily pretreated patients with relapsed or refractory m...
-
Article
Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations
Cryopreservation and thawing of haematopoietic stem cells are associated with cell loss and infusion-related toxicities. We analysed viability, total nucleated cell (TNC) and CD34+ cell recovery, and infusion-...
-
Article
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma
Multiple myeloma (MM) is a B-cell neoplasia caused by the proliferation of clonal plasma cells, primarily in the bone marrow (BM). The role of the BM microenvironment in the pathogenesis of the disease has bee...
-
Article
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients
Fludarabine (FDR) therapy gives a response rate of about 30% in previously treated patients with Waldenström's macroglobulinemia (WM). The combination of FDR and cyclophosphamide (Cy) has been shown to be effe...
-
Chapter
Amyloidosis: Round Table
During this round table we should discuss the best choice of treatment of amyloidosis at the present time, and we should try to defiine future perspectives. If we consider treating patients with conventional c...
-
Chapter
New therapeutic approaches for the myeloma patient with and without renal failure
Multiple myeloma (MM) remains a universally fatal malignancy and limited advances in its treatment have been made since the introduction, in the early 1960s, of alkylating agents. Median survival time from dia...
-
Article
Evaluating high dose therapy in Multiple Myeloma: Use of quality-adjusted survival analysis
Purpose: To incorporate quality-of-life considerations in assessing high dose therapy (HDT) for patients with Multiple Myeloma (MM). Patients and methods: A quality-adjusted survival analysis, using the quality-...
-
Article
Changing use of intensive care for hematological patients:
Objective: Intensivists generally view patients with hematological malignancies as poor candidates for intensive care. Nevertheless, hematologists have recently developed more aggressive treatment protocols capab...
-
Chapter
High Dose Chemotherapy and Blood Stem Cell Autologous Graft in Multiple Myeloma
Limited progress in the treatment of multiple myeloma (MM) has been obtained since the introduction of melphalan more than 20 years ago.Response rates to conventional therapy are only in the order of 50% and m...